ABIOMED Financial Statements (ABMD)
|
|
|
|
Report date
|
|
|
21.05.2021 |
30.09.2021 |
31.12.2021 |
31.03.2022 |
20.05.2022 |
|
03.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
847.5 |
|
|
1 032 |
1 032 |
|
1 083 |
|
Operating Income, bln rub |
|
|
229.6 |
|
|
140.7 |
372.7 |
|
254.1 |
|
EBITDA, bln rub |
? |
|
246.9 |
|
|
190.6 |
400.8 |
|
287.4 |
|
Net profit, bln rub |
? |
|
225.5 |
|
|
136.5 |
136.5 |
|
281.3 |
|
|
OCF, bln rub |
? |
|
274.6 |
|
|
|
285.4 |
|
160.5 |
|
CAPEX, bln rub |
? |
|
53.4 |
|
|
|
35.8 |
|
27.3 |
|
FCF, bln rub |
? |
|
221.2 |
|
|
|
249.6 |
|
133.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
|
|
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
456.1 |
|
|
586.9 |
586.9 |
|
624.3 |
|
Cost of production, bln rub |
|
|
161.9 |
|
|
188.2 |
188.2 |
|
204.4 |
|
R&D, bln rub |
|
|
121.9 |
|
|
163.4 |
163.4 |
|
170.1 |
|
Interest expenses, bln rub |
|
|
0.000 |
|
|
0.000 |
49.8 |
|
94.2 |
|
|
Assets, bln rub |
|
|
1 494 |
1 530 |
1 593 |
1 673 |
1 673 |
|
1 697 |
|
Net Assets, bln rub |
? |
|
1 330 |
1 385 |
1 433 |
1 503 |
1 503 |
|
1 540 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
583.7 |
650.6 |
669.2 |
758.6 |
758.6 |
|
820.4 |
|
Net debt, bln rub |
|
|
-583.7 |
-650.6 |
-669.2 |
-758.6 |
-758.6 |
|
-820.4 |
|
|
Ordinary share price, rub |
|
|
318.7 |
325.5 |
359.2 |
331.2 |
331.2 |
|
377.5 |
|
Number of ordinary shares, mln |
|
|
45.1 |
|
|
45.1 |
45.4 |
|
45.4 |
|
|
Market cap, bln rub |
|
|
14 387 |
0 |
0 |
14 952 |
15 053 |
|
17 126 |
|
EV, bln rub |
? |
|
13 804 |
-651 |
-669 |
14 194 |
14 295 |
|
16 306 |
|
Book value, bln rub |
|
|
1 204 |
1 265 |
1 315 |
1 387 |
1 381 |
|
1 417 |
|
|
EPS, rub |
? |
|
5.00 |
|
|
3.02 |
3.00 |
|
6.20 |
|
FCF/share, rub |
|
|
4.90 |
|
|
0.00 |
5.49 |
|
2.94 |
|
BV/share, rub |
|
|
26.7 |
|
|
30.7 |
30.4 |
|
31.2 |
|
|
EBITDA margin, % |
? |
|
29.1% |
|
|
18.5% |
38.8% |
|
26.5% |
|
Net margin, % |
? |
|
26.6% |
|
|
13.2% |
13.2% |
|
26.0% |
|
FCF yield, % |
? |
|
1.54% |
0.00% |
0.00% |
0.00% |
1.66% |
|
0.78% |
|
ROE, % |
? |
|
17.0% |
0.00% |
0.00% |
9.08% |
9.08% |
|
18.3% |
|
ROA, % |
? |
|
15.1% |
0.00% |
0.00% |
8.16% |
8.16% |
|
16.6% |
|
|
P/E |
? |
|
63.8 |
|
|
109.5 |
110.3 |
|
60.9 |
|
P/FCF |
|
|
65.0 |
|
|
|
60.3 |
|
128.6 |
|
P/S |
? |
|
17.0 |
|
|
14.5 |
14.6 |
|
15.8 |
|
P/BV |
? |
|
12.0 |
0.00 |
0.00 |
10.8 |
10.9 |
|
12.1 |
|
EV/EBITDA |
? |
|
55.9 |
|
|
74.5 |
35.7 |
|
56.7 |
|
Debt/EBITDA |
|
|
-2.36 |
|
|
-3.98 |
-1.89 |
|
-2.85 |
|
|
R&D/CAPEX, % |
|
|
228.3% |
|
|
|
456.9% |
|
623.6% |
|
|
CAPEX/Revenue, % |
|
|
6.30% |
|
|
0.00% |
3.47% |
|
2.52% |
|
| ABIOMED shareholders |
